This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Severe Diarrhea Risk Linked to PPIs Prompts FDA Warning
Limiting Dose, Duration of Use Can Reduce Threat of Side Effects
By News Staff
AHRQ Resources Focus on Clostridium difficile Infection
The full report can be downloaded from the AHRQ website, as can an executive summary of the report, clinician and consumer research summaries, and related resources.
PPIs, which reduce the production of stomach acid, are marketed under various brand and generic drug names as prescription and OTC products. A complete list of PPIs can be found at the FDA website.
The agency said it is working with manufacturers to include information about the increased risk of CDAD in PPI product labels. The FDA also is reviewing the risk of CDAD in users of histamine H2 receptor blockers, which are used to manage the same types of conditions PPIs treat.
Physicians and other health care professionals can report adverse events or side effects related to the use of PPIs or other agents to the FDA's MedWatch Safety Information and Adverse Event Reporting Program online or by phone at (800) 332-1088.